Donaldson Capital Management LLC purchased a new position in Celgene Co. (NASDAQ:CELG) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 3,575 shares of the biopharmaceutical company’s stock, valued at approximately $355,000.
Other large investors also recently bought and sold shares of the company. Bartlett & Co. LLC increased its position in Celgene by 143.2% during the third quarter. Bartlett & Co. LLC now owns 535 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 315 shares during the last quarter. Tibra Equities Europe Ltd raised its position in shares of Celgene by 144.2% in the 3rd quarter. Tibra Equities Europe Ltd now owns 525,134 shares of the biopharmaceutical company’s stock valued at $52,146,000 after purchasing an additional 310,134 shares during the last quarter. Gabelli Funds LLC increased its holdings in Celgene by 4.0% in the 3rd quarter. Gabelli Funds LLC now owns 828,055 shares of the biopharmaceutical company’s stock worth $82,226,000 after buying an additional 31,630 shares during the period. Mackay Shields LLC increased its holdings in Celgene by 21.3% in the 3rd quarter. Mackay Shields LLC now owns 128,896 shares of the biopharmaceutical company’s stock worth $12,799,000 after buying an additional 22,604 shares during the period. Finally, GABELLI & Co INVESTMENT ADVISERS INC. increased its holdings in Celgene by 8.2% in the 3rd quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 544,390 shares of the biopharmaceutical company’s stock worth $54,058,000 after buying an additional 41,470 shares during the period. 72.31% of the stock is owned by hedge funds and other institutional investors.
CELG has been the topic of a number of analyst reports. Leerink Swann set a $115.00 price objective on shares of Celgene and gave the stock a “hold” rating in a research note on Friday, November 1st. Mizuho reaffirmed a “hold” rating and set a $100.00 price objective on shares of Celgene in a research note on Sunday, October 20th. Zacks Investment Research raised shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective on the stock in a research note on Tuesday, July 23rd. Cowen reaffirmed a “hold” rating and set a $102.00 price objective on shares of Celgene in a research note on Tuesday, July 30th. Finally, Standpoint Research cut shares of Celgene from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, nineteen have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $97.31.
In other Celgene news, insider Terrie Curran sold 11,338 shares of Celgene stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the sale, the insider now owns 13,493 shares of the company’s stock, valued at approximately $1,325,957.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.39% of the company’s stock.
Shares of CELG stock traded up $0.47 during trading hours on Friday, reaching $109.47. The company had a trading volume of 457,166 shares, compared to its average volume of 3,870,767. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.80 and a current ratio of 2.89. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $109.07. The company has a market capitalization of $76.64 billion, a P/E ratio of 14.39, a price-to-earnings-growth ratio of 0.51 and a beta of 1.41. The stock’s fifty day simple moving average is $102.33 and its 200 day simple moving average is $96.68.
Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.70 by $0.29. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The business had revenue of $4.52 billion during the quarter, compared to analyst estimates of $4.39 billion. During the same quarter last year, the firm earned $2.29 earnings per share. The company’s revenue for the quarter was up 16.1% compared to the same quarter last year. As a group, equities analysts expect that Celgene Co. will post 10.7 earnings per share for the current year.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: Portfolio Manager
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.